News

Date Title View
Toggle Summary Aerie Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
Conference Call and Webcast Today, August 1 st , at 5:00 p.m. ET IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of
View HTML
Toggle Summary Aerie Pharmaceuticals Enters into Collaboration Agreement with DSM Focused on Technology to Potentially Deliver Aerie Compounds to Treat Retinal Diseases such as Wet AMD
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), (the "Company"), announced today that its second quarter 2017 financial results will be released after the market closes on Tuesday, August 1, 2017 . Following the release, the Company will host a live conference call and
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Richard A. Halprin as Director of Professional Affairs
IRVINE, Calif. --(BUSINESS WIRE)--Jul. 25, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results
Roclatan™ Successfully Demonstrates a Positive Safety Profile and Efficacy Levels Consistent with Previously Reported Results Conference Call and Webcast Today, July 19 , at 5:00 p.m. ET IRVINE, Calif. --(BUSINESS WIRE)--Jul. 19, 2017-- Aerie Pharmaceuticals, Inc.
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at Two Investor Conferences in June
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Vicente
View HTML
Toggle Summary Aerie Pharmaceuticals Raises $125 Million in ATM Sales and Upsized Follow-On Offering
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Public Offering of Common Stock
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results
Roclatan™ Successfully Achieves Primary Efficacy Endpoint in Mercury 2 Study Conference Call and Webcast Today, May 24 , at 5:00 p.m. ET IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development,
View HTML
Toggle Summary Aerie Pharmaceuticals Announces New Hires
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointments
View HTML